Document is current
Any future updates will be listed below
-
Authors
Schuermans, Art https://orcid.org/0000-0001-8146-9692
Pournamdari, Ashley B.
Lee, Jiwoo https://orcid.org/0000-0003-0555-585X
Bhukar, Rohan
Ganesh, Shriienidhie https://orcid.org/0000-0002-4226-7526
Darosa, Nicholas
Small, Aeron M.
Yu, Zhi https://orcid.org/0000-0003-4810-3474
Hornsby, Whitney
Koyama, Satoshi https://orcid.org/0000-0002-9286-0360
Kooperberg, Charles
Reiner, Alexander P.
Januzzi, James L.
Honigberg, Michael C. https://orcid.org/0000-0001-8630-5021
Natarajan, Pradeep https://orcid.org/0000-0001-8402-7435
-
Funding
Funding for this research was provided by:
Massachusetts General Hospital (Paul & Phyllis Fireman Endowed Chair in Vascular Medicine)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL127564, K08HL166687)
Belgian American Educational Foundation
American Heart Association (940166, 979465)
- License Information
-
More Information
Article History
Received: 4 January 2024
Accepted: 23 October 2024
First Online: 21 November 2024
Inclusion and ethics
: Inclusion and ethics standards have been reviewed where applicable.
: J.L.J. reports board membership of Imbria Pharmaceuticals; grant support from Abbott Diagnostics, AstraZeneca, BMS, HeartFlow and Novartis; previous consulting income from Abbott Diagnostics, AstraZeneca, Bayer, Beckman Coulter, Jana Care, Janssen, Novartis, Quidel, Roche Diagnostics and Siemens; and clinical end point committee/data safety monitoring board membership for Abbott, Bayer, AbbVie, CVRx, Pfizer, Roche Diagnostics and Takeda. M.C.H. reports consulting fees from CRISPR Therapeutics and Comanche Biopharma; advisory board service for Miga Health; and grant support from Genentech. P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech/Roche and Novartis; personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, TenSixteen Bio and Tourmaline Bio; equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli and TenSixteen Bio; and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. The other authors declare no competing interests.
